Wladimir Hogenhuis
Independent DirectorDr. Wladimir Hogenhuis, M.D., M.B.A., also known as Vlad, serves as Chief Executive Officer of Driver Bioengineering, Inc. since April 2022. He is currently the Chief Executive Officer and President of Chimera Bioengineering. He serves as Independent Director at Rezolute, Inc. since March 02, 2021. Dr. Hogenhuis served as Chief Operating Officer at Ultragenyx Pharmaceutical Inc. since September 28, 2018 until January 2020. Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, Specialty Pharmaceuticals of GlaxoSmithKline Plc. from December 2012 to September 2018. Dr. Hogenhuis held various leadership posts in Merck & Co. Inc., including general manager of the company's U.S. operations in dermatology and ophthalmology, general manager of Belgium and Luxembourg and head of marketing in China. Dr. Hogenhuis has tremendous global cross-functional experience and a track record of driving growth, building and leading multi-national teams. Dr. Hogenhuis’s strong medical and business background provides the high quality insight and experience needed to help Ultragenyx achieve its ambitious goals with its multi-mode product portfolio. Dr. Hogenhuis is veteran of the pharmaceutical industry. He spent at GSK, wherehe was initially responsible for the it's Cardiovascular, Metabolic and Neurosciences Franchise and later led the Specialty Franchise. At GSK he had strategic responsibility and commercial accountability for novel medicines for lupus disease, type II diabetes and rheumatoid arthritis, with six phase 3 compounds in rheumatology, oncology, dermatology and nephrology. Dr. Hogenhuis currently serves on the board of GATT Technologies B.V., a private company in the Netherlands developing novel surgical hemostats and sealants. He is also a board member of IHP Therapeutics, a private company based in San Francisco, developing a therapy for the treatment of COVID-19 slated to enter clinical development later this year. He previously served as a member of the Board of Directors of Vision 2020, a global initiative for the elimination of avoidable blindness, a joint programme of the World Health Organization and the International Agency for the Prevention of Blindness. He was also responsible for the integration of manufacturing and research in shaping product launches in therapeutic areas new to GSK. Prior to GSK, Dr. Hogenhuis spent at Merck & Co. in a variety of leadership and operational roles including General Manager for the Neuroscience, Dermatology & Ophthalmology U.S. Operations, General Manager of Belgium and Luxemburg and Head of Marketing in China with responsibility for all of Merck’s products. Dr. Hogenhuis has a Medical Degree in Medicine from Leiden University in the Netherlands and an MBA degree from the Wharton School of Business. He served as a National Institutes of Health Fellow in Medical Decision Making at Tufts Medical Center in Boston and as a Surgeon Lieutenant in the Royal Dutch Navy.
Positions
- Company NameRezolute, Inc.Stock CodeRZLTPositionIndependent DirectorColleagues
- NCNevan Charles ElamFounder, CEO & Acting Chairman of the Board
- DGDaron G. EvansChief Financial & Business Officer
- BKBrian Kenneth RobertsChief Medical Officer
- SKSunil KarnawatChief Commercial Officer
- MRMichael R. DeperroSenior VP & Head of Operations
- GMGilbert M. LabrucherieIndependent Director
- NCNerissa C. KreherIndependent Director
- JMJerrold M. OlefskyMember of the Scientific Advisory Board
